Clinical Trial Update: Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) [Phase 2]

View source ↗

Summary

Phase 2B study evaluating ASN002 for moderate-to-severe atopic dermatitis has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ASN002

Snippet

Sponsor: Asana BioSciences | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-11-15